Mark A. Velleca - Sep 15, 2023 Form 4 Insider Report for Black Diamond Therapeutics, Inc. (BDTX)

Role: PRESIDENT & CEO, Director
Signature: /s/ Brent Hatzis-Schoch, Attorney-in-Fact
Stock symbol: BDTX
Transactions as of: Sep 15, 2023
Transactions value $: $18,749
Form type: 4
Date filed: 9/18/2023, 05:26 PM
Previous filing: Aug 10, 2023
Next filing: Feb 15, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BDTX	Common Stock	Award	$18.7K	+5.21K	+12.61%	$3.60	46.5K	Sep 15, 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BDTX	Stock Option (Right to Buy)	Award	$0	+1M		$0.00	1M	Sep 17, 2023	Common Stock	1M	$3.55	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were issued in accordance with the Issuer's Fourth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.
F2	The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 14, 2023.
F3	25% of the shares subject to this option shall vest and become exercisable on September 17, 2024, with the remainder vesting in 36 equal monthly installments thereafter.